US 10441645
MSLN targeting DNA vaccine for cancer immunotherapy
granted A61KA61K2039/522A61K2039/523
Quick answer
US patent 10441645 (MSLN targeting DNA vaccine for cancer immunotherapy) held by Vaximm AG expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vaximm AG
- Grant date
- Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K2039/522, A61K2039/523, A61K2039/53, A61K2039/542